- SARS-CoV-2 (COVID-19) infection in pregnant women: characterization of
- 2 symptoms and syndromes predictive of disease and severity through real-time,
- 3 remote participatory epidemiology.
- 5 Erika Molteni^{1\$} and Christina M. Astley²\$ and Wenjie Ma³\$, Carole H Sudre¹, Laura A. Magee⁴,
- 6 Benjamin Murray¹, Tove Fall⁵, Maria F. Gomez⁶, Neli Tsereteli⁶, Paul W. Franks⁶, John S.
- 7 Brownstein², Richard Davies⁷, Jonathan Wolf⁷, Tim D Spector⁸, Sebastien Ourselin¹, Claire J
- Steves⁸, Andrew T Chan^{3#} and Marc Modat^{1#}.
- 9 1. School of Biomedical Engineering & Imaging Sciences, King's College London, London, United Kingdom.
- 2. Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA.
- 4. Department of Women and Children's Health, School of Life Course Sciences and the Institute of Women and
- Children's Health, King's College London, London, United Kingdom.
- 5. Department of Medical Sciences and Science for Life Laboratory, Uppsala University, Sweden.
- 15 6. Department of Clinical Sciences, Lund University Diabetes Centre, Jan Waldenströms gata 35, SE-21428,
- 16 Malmo, Sweden.

1

4

- 7. Zoe Global Limited, London, United Kingdom.
- 18 B. Department of Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom.
- 20 \$ These authors contributed equally
- # These authors contributed equally
- 22 Address correspondence to:
- 23 Erika Molteni. *PhD*
- 24 School of Biomedical Engineering and Imaging Sciences
- 25 King's College London

27 9th floor, Becket House

26

32

28 1 Lambeth Palace Road

29 SE1 7EU London, United Kingdom

30 erika.molteni@kcl.ac.uk

31 ORCID: orcid.org/0000-0001-7773-81-40

Pregnancy with SARS-CoV-2 has no higher risk of severe symptoms. Underlying lung disease or cardiac condition can increase risk.

Tweetable abstract

Abstract

41

42

43

44

45

46

47

48

49

51

53

54

55

56

57

58

59

61

63

women who were hospitalized.

Objective: To test whether pregnant and non-pregnant women differ in COVID-19 symptom profile and severity. To extend previous investigations on hospitalized pregnant women to those who did not require hospitalization. **Design:** Observational study prospectively collecting longitudinal (smartphone application interface) and cross-sectional (web-based survey) data. Setting: Community-based self-participatory citizen surveillance in the United Kingdom, Sweden and the United States of America. **Population:** Two female community-based cohorts aged 18-44 years. The discovery cohort was 50 drawn from 1,170,315 UK, Sweden and USA women (79 pregnant tested positive) who selfreported status and symptoms longitudinally via smartphone. The replication cohort included 52 1,344,966 USA women (134 pregnant tested positive) who provided cross-sectional self-reports. **Methods:** Pregnant and non-pregnant were compared for frequencies of symptoms and events, including SARS-CoV-2 testing and hospitalization rates. Multivariable regression was used to investigate symptoms severity and comorbidity effects. **Results:** Pregnant and non-pregnant women positive for SARS-CoV-2 infection were not different in syndromic severity. Pregnant were more likely to have received testing than non-pregnant, despite reporting fewer symptoms. Pre-existing lung disease was most closely associated with the syndromic severity in pregnant hospitalized women. Heart and kidney diseases and diabetes 60 increased risk. The most frequent symptoms among all non-hospitalized women were anosmia [63% pregnant, 92% non-pregnant] and headache [72%, 62%]. Cardiopulmonary symptoms, 62 including persistent cough [80%] and chest pain [73%], were more frequent among pregnant

64 Conclusions: Symptom characteristics and severity were comparable among pregnant and non-65 pregnant women, except for gastrointestinal symptoms. Consistent with observations in non-66 pregnant populations, lung disease and diabetes were associated with increased risk of more severe 67 SARS-CoV-2 infection during pregnancy. 68 69 70 71 **Keywords**: pregnancy; community SARS-CoV-2 symptoms; SARS-CoV-2 72 risk factors; SARS-CoV-2 severity; digital health; citizen science; syndromic surveillance; 73 anosmia. 74

Main text

75

76

1. Introduction

The COVID-19 pandemic is caused by the SARS-CoV-2, a newly identified enveloped RNA-β-77 coronavirus ^{1,2}. Early on, pregnant women were regarded as vulnerable group, at greater risk of 78 79 severe morbidity and mortality, based on previous studies of smaller coronavirus outbreaks, and the theoretical risks associated with immunosuppression of pregnancy ^{3–5}. However, substantial 80 81 literature has now documented that, among hospitalized pregnant women, antecedent symptoms and risk factors for severe disease are similar to those outside pregnancy ⁶, and few hospitalized 82 83 pregnant women require admission to intensive care or intubation, although preterm birth, 84 Caesarean delivery, and stillbirth may be increased compared with women without COVID-19, and vertical transmission possible (86 studies to 8 Jun 2020) ^{7–10}. SARS-CoV-2 positive patients 85 86 develop dry cough, fever, dyspnea, fatigue and bilateral lung infiltrates on imaging in the severe cases ¹¹. Hospitalized pregnant women positive for SARS-CoV-2 manifest similar symptoms ^{7,12,13}. 87 88 However, little is known about pregnant women affected by SARS-CoV-2 infection in the community, many of whom recover without hospitalization ¹⁴. 89 90 Smartphone and web-based applications for population-based syndromic surveillance are citizen science tools that can facilitate rapid acquisition of extensive epidemiological data as a pandemic 91 evolves ¹⁵. These data can inform public-health policies, enhance the speed of the healthcare 92 response, shape the community services, and alert the general population to urgent health threats ¹⁶. 93 94 Smartphone applications (apps) were used prior to the COVID-19 pandemic to remotely advise on prenatal health, and maternal health behaviours, including gestational weight gain and smoking 95 cessation ¹⁷. Many eHealth initiatives were launched at the onset of the pandemic, with most using 96 single, cross-sectional reporting methods to inform SARS-CoV-2 epidemiology ¹⁸. We present 97 98 findings from a unique, longitudinal community-based symptom-tracking system that identified

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

both test positive and suspected (but untested) SARS-CoV-2 infected pregnant women, who were followed prospectively to assess the need for hospitalization. Furthermore, we replicated key findings, using an independent, cross-sectional symptom survey. We present data from a cohort of women of childbearing age, including pregnant women who report test-positive SARS-CoV-2. Despite presenting a wide spectrum of disease manifestations, these pregnant women rarely required hospitalization. In order to include non-tested subjects who developed symptoms during the onset of the pandemic, when testing resources were still limited, we developed a model to predict positivity to SARS-CoV-2 based on symptoms, specific to female population in childbearing age. We sought to characterize the differences in the SARS-CoV-2 symptom profiles and severity between pregnant and nonpregnant women who did and did not receive hospitalization. We identified demographic characteristics and comorbidities that modified symptom severity of SARS-CoV-2 in pregnancy. 2. Materials and methods 2.1 Study Populations We developed a symptom-based prediction method to identify suspected COVID-19 cases among women 18-44 years of age from a discovery cohort. Results were replicated in an independent, cross-sectional cohort with different survey methodology. **Discovery Cohort.** The COVID Symptom Study smartphone-based application (app), developed by Zoe Global Limited, and having almost four million users from the general population in UK, 280,000 from USA and around 175,000 from Sweden. Users self-report daily information about their overall health status, as well as their symptoms (from a pre-defined list, to standardise input) ^{19, 20}. We included all pre-menopausal (if menopausal status was reported) women aged 18 to 44 years, who used the app between 24 March and 7 June 2020, and specified their pregnancy status at

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

baseline (pregnant or not pregnant) included symptom profiles, outcomes on testing positive for SARS-CoV-2, and hospitalization (Supplementary Material 1). Replication Cohort. The Facebook COVID-19 Symptom survey, launched in the USA and hosted by the Carnegie Mellon Delphi Research Center. Surveys were conducted using sampling strategies and survey weights to ensure respondents were representative of the USA source population ²¹ (Supplementary Material 1). Using data from launch (6 April 2020) through 7 June 2020, we identified surveys from 1,344,966 female respondents who indicated their pregnancy status and age 18-44 years ²². Users specified if they had experienced specific symptoms over the last 24 hours, in addition to answering demographic and infection-related questions. 2.2 Pregnancy groups, symptoms, syndromes and outcomes **Pregnancy status:** Women were divided into pregnant and non-pregnant subgroups, based on selfreported pregnancy status, ascertained once near the start of follow-up in the discovery cohort, and at each survey for the replication cohort. Gestational age, at the time pregnancy was ascertained, was available only for the discovery cohort. **COVID-19 Test and Suspected Positive:** Self-reported COVID-19 testing was used to identify women with SARS-CoV-2 infection (termed test positive). Test positives were considered symptomatic positive if they reported at least one of the tracked symptoms. The type of test (e.g. PCR, serology) was not ascertained, and those reporting a pending test were excluded. Suspected positive cases were imputed, based on a previously published method for the computation of a test-positive prediction score ²⁰. The model was retrained for pregnancy age distribution, based on a bootstrapped train-test scheme in the discovery cohort, and using a strict mapping to equate symptoms ascertained in both the discovery and replication cohorts. We defined the outcome of suspected COVID-19 (termed suspected positive) for anyone with a score-based imputation probability above a computed threshold (Supplementary Material 2).

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

Hospitalization and Syndrome Severity: Individuals were considered to have been hospitalized when they indicated being either admitted to or discharged from hospital in their daily reporting, within one week before/after reporting at least one of the tracked symptoms. Symptoms, test results and hospitalization can be reported anytime and with no interdependencies in the app, and symptom reporting is not censored after input of test results. Symptom severity was thus defined as the weighted sum of symptoms based on peak presentation when comparing individuals reporting hospital visit with individuals who did not, in the training set of the discovery cohort (Supplementary Material 3). Symptoms were equated in the two cohorts. The weighting was then normalized so that the severity index ranges from 0 (no symptom) to 1 (all symptoms). 2.4 Statistical analysis A power analysis was conducted to assess the suitability of the samples size. To account for the difference in age distributions between pregnant and non-pregnant groups, age-standardization was performed, by calculating weights for the non-pregnant women, to standardize to the agedistribution of the pregnant population (Supplementary materials 4 and 5). **Symptoms.** To explore differences in the symptom profile between pregnant and non-pregnant women who tested or were suspected positive for SARS-CoV-2 and who also required hospitalization or sought care, we applied univariate unconditional age-weighted logistic regression for each of 18 symptoms ascertained in either the discovery cohort, the replication or in both. We then conducted multivariate analysis on symptoms grouped into clusters by body system, as shown in Table 2, and normalized to range from 0 to 1. **Severity of syndrome.** To assess symptom severity differences between pregnant and non-pregnant women who tested or were suspected positive for SARS-CoV-2 infection and were hospitalized, univariate unconditional age-weighted regression was applied to the pregnant and non-pregnant groups of the discovery cohort, with the severity index as a response variable. The analysis was

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

repeated for this cohort among those who reported to have been 'seen at a hospital for their symptoms', conditional on those who predicted or tested positive for SARS-CoV-2. **Hospitalization.** To explore differences in the symptom profiles between hospitalized and nonhospitalized pregnant women positive for SARS-CoV-2, the frequency and percentage of women reporting each symptom were calculated for the discovery cohort. Symptoms were ranked from the most to the least frequently reported. **Disease modifiers.** To identify demographic characteristics, comorbidities and pre-conditions associated with COVID-19 symptom severity in pregnancy, a multivariate unconditional regression was applied to each dataset, with the severity index as a response variable and age, diabetes, heart, lung (and asthma) and kidney diseases as factors. As the regression investigated within-group factors, age-weighting was not applied. Bonferroni correction for multiple tests was applied. Statistical analyses were performed using STATA version 16 (discovery cohort) and R 3.6.3 (replication cohort). 3. Results Cohort Characteristics and COVID-19 Outcomes. The discovery cohort (N=400,750 participants) was obtained from women (aged 18-44) in the test subset only. It includes longitudinal records from 14,049 pregnant and 386,701 non-pregnant women who had a median duration of follow-up of 18 days (IQR [6-34]) and contributed to an average of 6.6 reports per woman. Among the 45% of pregnant women who self-reported their gestation week at baseline, 14% were in the first trimester, 43% were in the second trimester, and 43% were in the third trimester. The replication cohort consisted of N= 1,344,966 cross-sectional surveys from women aged 18-44. Onetime surveys were administered over the 9 week period, at average rate of about 149 thousand

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

surveys per week, using survey methodology. There were 41,796 surveys from women who indicated they were pregnant (3.1% of the source population). Demography was consistent with US age-specific pregnancy rates and stable over the survey period ²³. Demographic details are shown in Table 1, together with testing rates. In the discovery cohort, we identified 629 and 25,061 pregnant and non-pregnant women, respectively, who were suspected positive for SARS-CoV-2 infection based on the symptom-score-based imputation method. Of these suspected positive, 21 (3.3%) pregnant and 591 (2.4%) non-pregnant were hospitalized, respectively. In the replication cohort, the proportion of 1,076 (2.9%) suspected positive pregnant was slightly lower compared to 44,772 (4.0%) suspected positive non-pregnant. Insert Table 1 about here Validation of the imputation method in a subset of the discovery cohort, and in the replication cohort is depicted in Figure 1, with additional sensitivity analyses in Supplementary Material 2. Insert Figure 1 about here Symptomatic, Syndromic and Severity Predictors: Frequency of symptoms and body system clusters is reported in Table 2, and graphically in Figure 2. In the discovery cohort, the most frequent symptoms in the hospitalized pregnant women positive for SARS-CoV-2 were persistent cough, headache and anosmia (all 80.0%), chest pain (73.3%), sore throat and fatigue (66.7%). In the replication cohort, among pregnant test positive women who were seen at the hospital for their illness, the most frequent symptoms were fatigue (87.5%), cough (84.6%), nausea or vomiting (78.2%), muscle pain (76.2) and anosmia (75.2%). Insert Table 2 about here In the discovery cohort, univariate analysis on each symptom found significant effect of pregnancy for decreased odds of skipped meals (OR 0.5, 95% CI 0.2 to 0.9) and of delirium (OR 0.2, 95% CI

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

Insert Figure 3 about here

0.1 to 0.6) but not for the other symptoms. Multivariate logistic regression found lower frequency of neurologic symptoms (OR 0.3, 95% CI 0.2 to 0.6) for the positive hospitalized pregnant vs. non pregnant women. Among test positives in the replication cohort, pregnancy status was most strongly associated with increased odds of nausea or vomiting (OR 2.3, 95% confidence interval 1.5 to 3.5) and the *oropharyngeal* cluster (OR 1.6, 95% CI 1.2 to 2.2), even among test positives reporting being seen at a hospital for their illness (OR 3.4, 95% CI 1.3 to 8.8 and OR 2.1, 95% CI 1.1 to 4.1, respectively), indicating how questions are asked can impact symptom profiles in this population (all age-standardized and p<5e-05 Bonferroni corrected). Insert Figure 2 about here Univariate weighted regression also showed that pregnancy had no statistically significant effect on the severity of manifestation of SARS-CoV-2 infection, when expressed as 'severity index' in both cohorts (p>0.001, uncorrected to test the null hypothesis). In the discovery cohort, overall duration of disease was similar for pregnant and non-pregnant women. However, time to peak of symptom manifestation was statistically longer in pregnant women (mean time = 2.8 days) than in nonpregnant (2.2 days, p=5.5e-7), though clinically the difference may not be significant. In the replication cohort, pregnant women who tested positive and reported being seen at the hospital similarly reported a longer duration of illness. As mentioned above, in the discovery cohort hospitalized positive pregnant women manifested persistent cough, headache and anosmia (all 80%), chest pain (73.3%), sore throat and fatigue (66.7%) as the most frequent symptoms. Non-hospitalised pregnant women positive for SARS-CoV-2 reported headache (71.9%), anosmia (62.5%), persistent cough (57.8%) and skipped meals (48.4%) most commonly (Figure 3). See Supplementary Material 6 for full list of symptoms and their associated prevalence.

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

Comorbidities: Lung disease was the comorbidity that most impacted on the severity of symptoms in pregnant positive women (t=4.1 for discovery cohort; t=14.1 for replication cohort, all pval<0.0001 Bonferroni corrected). Insert Table 3 about here In the replication cohort heart disease (t=7.1) also impacted on the severity of symptoms, followed by kidney disease (t=4.6) and diabetes (t=3.6, all significant after Bonferroni correction at pval<0.0001). 4. Discussion Main Findings. We studied two large cohorts of women, tested and suspected SARS-CoV-2 positive, with self-reported pregnancy status, symptoms and outcomes through participative surveillance. Pregnant women reported more frequent testing for SARS-CoV-2 than non-pregnant women, but generally did not experience more severe disease. Disease trajectories were similar, and the time from onset to peak of symptoms was only slightly longer in pregnant than non-pregnant women (2.8 vs. 2.2 days). Gastrointestinal symptoms were different in pregnant and non-pregnant women with poor outcomes, with decreased skipped meals in the discovery cohort and increased nausea or vomiting in the replication cohort. Neurologic symptoms (only surveyed in the discovery cohort) were decreased in pregnant women. The current epidemiologic literature is largely based on pregnant women admitted to the hospital, which provides a narrow view of the spectrum of SARS-CoV-2 infection in all pregnant women. Our data show the preponderance of tested positive and even suspected positive pregnant women were not seen at or admitted to the hospital for their illness; most pregnant women reported they recover in the community, as was observed by Lokken et al. ²⁴. Cardiopulmonary symptoms were

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

more frequently reported by pregnant women who were hospitalised. Notably, pre-existing lung disease was confirmed as the largest risk factor to develop more severe COVID-19 symptoms in pregnancy, as it is outside of pregnancy. Heart disease, kidney disease and diabetes were also risk factors. **Interpretation.** Pregnant women are considered a high-risk group in UK and were considered high risk in the USA early in the pandemic. This likely contributed to the higher testing proportion but lower positives results among pregnant women vs. non-pregnant. Hospitalized pregnant women presented lower frequency of neurologic symptoms, especially delirium, which were only measured in the discovery cohort. The replication cohort showed higher frequency of gastrointestinal symptoms among pregnant women with more severe outcomes, especially nausea or vomiting in pregnancy, which may be a feature of pregnancy itself (e.g. hyperemesis gravidum). Diarrhoea in positive pregnant women has been previously reported (rates between 8.8% and 14%) ^{25,26}. Syndrome severity did not differ between pregnant and non-pregnant women in both datasets. This posits an equivalent manifestation of SARS-CoV-2 infection in pregnant and non-pregnant, as already reported by Chen and others ^{9,12}. Pre-existing lung disease is the comorbidity with strongest impact on the SARS-CoV-2 infection severity in pregnant women in both cohorts. Lokken et al. ²⁴ similarly reported asthma as a primary risk factor for severe COVID-19 in pregnancy. Heart disease, kidney diseases and diabetes were also associated with severity in the replication cohort which had high enough prevalence of these conditions (related to survey-sampling to the general population) to detect an effect. These comorbidities are consistent with risk factors in the general, non-pregnant population; Li et al. observed chronic obstructive pulmonary disease, diabetes, hypertension, coronary heart disease and cerebrovascular diseases had the highest odd ratio for SARS-CoV-2 and admission to the intensive

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

care unit (ICU) ²⁷, while Kumar et al. found diabetes increased SARS-CoV-2 severity and mortality two-fold ²⁸. Cough, chest pain and dyspnea showed much higher incidence in the hospitalized pregnant women, indicating that cardiopulmonary symptoms are the major discriminant for hospitalization. Similarly, Ellington et al ²⁹, found increased ICU admissions and need of mechanical ventilation in pregnant women, although the cohort studied had higher frequency of underlying medical conditions, and might be less representative of the general pregnant population. Pregnant women with pre-existing lung disease or prominent cardiopulmonary symptoms may need special attention during the COVID-19 pandemic; lung disease had strongest impact on syndrome severity while cardiopulmonary symptoms were the main factor predicting hospitalization in pregnancy. Indeed, in pregnancy, cardiopulmonary reserve is limited which increases morbidity and complicates management when there are added physiologic stressors (e.g. asthma exacerbation) 30-³² ³³. Diabetes was more common in the pregnant women in our cohorts, likely related to gestational diabetes. We confirmed diabetes is associated to increased severity of SARS-CoV-2 symptoms ³⁴. This study leveraged two cohorts followed through remote, participatory epidemiology, enabling rapid assessment of COVID-19 in pregnancy. The longitudinal nature of the discovery dataset enabled the comparison of disease duration, time from onset to peak of symptoms, and hospitalization between pregnant and non-pregnant women, prospectively. Broadly, pregnancy does not substantially contribute to morbidity in our community-based cohorts. Clinicians should be more vigilant with pregnant who have pre-existing health conditions, prominent respiratory symptoms or a higher severity index -- as is the case in the general population. Further studies specifically targeting high-risk pregnancies and outcomes across the three trimesters may be warranted, to better define outcomes in this population. Also, we point out the need to interpret hospitalization rates and severity results in light of the policy changes, which can be dependent on the context or country.

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

Strengths and limitations. Participatory surveillance tools are crucial to epidemiological research and citizen science, as they increase population's awareness of urgent public health risks, promote public participation into science and enable inclusion in studies of large samples from the community within short time periods. Real-time public health data has been crucial in decisionmaking during the COVID-19 pandemic. However, user of smartphone applications and web-based surveys may not be representative of the general population, potentially limiting generalizability. Self-reported events may suffer from misclassification bias, which may be differential (e.g. ability to log hospitalization may be higher in less severely affected participants, test results known at the time of cross-sectional symptom reporting may differ). Median app usage was 18 days, which may be insufficient follow-up to ascertain all outcomes. In the discovery cohort, pregnancy status was only queried at the time of registration; women who became pregnant after registration may be misclassified. In addition, gestational age during the infection could not be assessed, as well as whether women were symptomatic at the time of delivery. The replication cohort was designed to be representative of USA population through survey sampling for the active user base and weights with raking to the USA census. Despite the different platforms and country of origin of users, the cross-sectional surveys showed similar results to the detailed longitudinal discovery cohort of technology-aware smartphone users. However, it was not possible to distinguish difference in methodology from country-specific effects. Additionally, we applied agestandardization to account for demographic structure inherent to pregnancy. Despite the differences in the UK, USA and Sweden testing guidelines and healthcare systems, morbidity with COVID-19 in pregnancy were comparable. We were able to develop and validate a prediction score for suspected positive, as well as a severity score for use in women of childbearing age, and these performed similarly in the cross-sectional survey data despite development using longitudinal symptom reports. This may be useful for obstetricians in the context of limited access to SARS-CoV-2 testing during this pandemic.

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

Funding

Conclusions. Our findings from two large real-time syndromic surveillance technologies provide evidence that most pregnant women in the community who are positive for SARS-CoV-2 are at similar risk of developing either increased morbidity or complex symptomatology compared with non-pregnant women. However, pre-existing lung or cardiac disease may exacerbate cardiopulmonary stress of pregnancy. Pregnant women with comorbidities appear to be at increased risk for severe disease, consistent with evidence from COVID-19 infection in the general population. Pregnant women with pre-existing conditions, similar to the general adult population, require careful monitoring for the evolution of their symptoms during SARS-CoV-2 infection. Acknowledgements Authors express gratitude to all the participants who entered data into the smartphone app and website, including study volunteers enrolled in the Coronavirus Pandemic Epidemiology (COPE) consortium and Carnegie Mellon Delphi Research Center. We thank the staff of Zoe Global, the Department of Twin Research at King's College London, the Clinical and Translational Epidemiology Unit at Massachusetts General Hospital, the Department of Clinical Sciences in Malmö at Lund University and the Department of Medical Sciences at Uppsala University for tireless work in contributing to the running of the study and data collection. **Declaration of interest** EM, CMA, WM, JB, MFG, MM have no conflict of interest. ATC previously served as an investigator on a clinical trial of diet and lifestyle using a separate mobile application that was supported by Zoe Global Ltd.

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

This work was supported by Zoe Global. The Department of Twin Research receives grants from the Wellcome Trust (212904/Z/18/Z) and Medical Research Council/British Heart Foundation Ancestry and Biological Informative Markers for Stratification of Hypertension (AIMHY; MR/M016560/1), and support from the European Union, the Chronic Disease Research Foundation, Zoe Global, the NIHR Clinical Research Facility and the Biomedical Research Centre (based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London). The School of Biomedical Engineering & Imaging Science and Centre for Medical Engineering at King's College London receive grants from the Wellcome/EPSRC Centre for Medical Engineering [WT 203148/Z/16/Z]. E.M. is funded by the 'Skills Development Scheme' of the Medical Research Council UK. C.M.A. is funded by NIDDK K23 DK120899 and the Boston Children's Hospital Office of Faculty Development Career Development Award. CHS is supported by an Alzheimer's Society Junior fellowship (AS-JF-17-011). W.M., J.S.B. and A.T.C. are supported by the Massachusetts Consortium on Pathogen Readiness (MassCPR) and Mark and Lisa Schwartz. Most of the mentioned funding schemes are externally peer reviewed for scientific quality, and rely on the involvement of patient and public panels in either the design or evaluation phases, or both.

References

381

- 382 1. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The
- species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and
- naming it SARS-CoV-2. Nature Microbiology. 2020.
- 385 2. Sironi M, Hasnain SE, Rosenthal B, Phan T, Luciani F, Shaw MA, et al. SARS-CoV-2 and
- 386 COVID-19: A genetic, epidemiological, and evolutionary perspective. Infection, Genetics
- and Evolution. 2020.
- 388 3. Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, Shek CC, et al. Pregnancy and perinatal
- outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol. 2004;
- 4. Park MH, Kim HR, Choi DH, Sung JH, Kim JH. Emergency cesarean section in an epidemic
- of the middle east respiratory syndrome: A case report. Korean J Anesthesiol. 2016;
- 5. Chui ML, Shell FW, Tse NL, Kam MC, Wai CY, Tin YW, et al. A case-controlled study
- comparing clinical course and outcomes of pregnant and non-pregnant women with severe
- acute respiratory syndrome. BJOG An Int J Obstet Gynaecol. 2004;
- 395 6. Panahi L, Amiri M, Pouy S. Risks of Novel Coronavirus Disease (COVID-19) in Pregnancy;
- a Narrative Review. Arch Acad Emerg Med. 2020;
- 7. Khalil A, Kalafata E, Benlioglua C, O'Brien P, Morris E, Draycott T, et al. SARS-CoV-2
- infection in pregnancy: A systematic review and meta- analysis of clinical features and
- pregnancy outcomes. EClinicalMedicine. 2020;100446.
- 400 8. Khalil A, von Dadelszen P, Draycott T, Ugwumadu A, Magee LA. Increase in the incidence
- of stillbirth during the COVID-19 pandemic. JAMA J Am Med Assoc. 2020; July 10.
- 402 9. Chen Y, Li Z, Zhang YY, Zhao WH, Yu ZY. Maternal health care management during the
- outbreak of coronavirus disease 2019. Journal of Medical Virology. 2020.
- 404 10. CDC Coronavirus Disease 2019 (COVID-19) People Who Need Extra Precautions Others At
- 405 Risk. If You Are Pregnant, Breastfeeding, or Caring for Young Children. 2020.
- 406 11. Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q, et al. Prevalence and severity of corona virus

407 disease 2019 (COVID-19): A systematic review and meta-analysis. Journal of Clinical 408 Virology. 2020. 409 12. Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C, et al. Characteristics and 410 outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in 411 UK: national population based cohort study. BMJ. 2020; 412 13. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and 413 intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a 414 retrospective review of medical records. Lancet. 2020; 415 14. Ceulemans M, Verbakel JY, Van Calsteren K, Eerdekens A, Allegaert K, Foulon V. SARS-416 CoV-2 Infections and Impact of the COVID-19 Pandemic in Pregnancy and Breastfeeding: 417 Results from an Observational Study in Primary Care in Belgium. Int J Env Res Public Heal. 418 2020;17(18):E6766. 419 15. McCullough PA, Eidt J, Rangaswami J, Lerma E, Tumlin J, Wheelan K, et al. Urgent need 420 for individual mobile phone and institutional reporting of at home, hospitalized, and 421 intensive care unit cases of SARS-CoV-2 (COVID-19) infection. Reviews in cardiovascular 422 medicine. 2020. 423 16. Brownstein JS, Freifeld CC, Madoff LC. Digital disease detection - Harnessing the web for 424 public health surveillance. New England Journal of Medicine. 2009. 17. 425 Hussain T, Smith P, Yee LM. Mobile Phone-Based Behavioral Interventions in Pregnancy to 426 Promote Maternal and Fetal Health in High-Income Countries: Systematic Review. JMIR 427 mHealth and uHealth. 2020. 428 18. mHealth solutions list [Internet]. p. http://mhealth-hub.org/mhealth-solutions-against-c. 429 Available from: http://mhealth-hub.org/mhealth-solutions-against-covid-19 430 19. Drew DA, Nguyen LH, Steves CJ, Menni C, Freydin M, Varsavsky T, et al. Rapid 431 implementation of mobile technology for real-time epidemiology of COVID-19. Science (80-432). 2020;

- 433 20. Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, et al. Real-time
- tracking of self-reported symptoms to predict potential COVID-19. Nat Med. 2020;
- 435 21. Facebook Questionnaire [Internet]. p. https://cmu.ca1.qualtrics.com/jfe/preview/SV_cT2ri.
- 436 Available from:
- 437 https://cmu.ca1.qualtrics.com/jfe/preview/SV_cT2ri3tFp2dhJGZ?Q_SurveyVersionID=curre
- 438 nt&Q_CHL=preview
- 439 22. Kreuter F, Barkay N, Bilinski A, Bradford A, Chiu S, Eliat R, et al. Partnering with
- Facebook on a university-based rapid turn-around global survey. Surv Res Methods.
- 441 2020;14(2).
- 23. CDC D. https://www.cdc.gov/nchs/data/databriefs/db136.pdf [Internet]. CDC data. 2020.
- 443 Available from: https://www.cdc.gov/nchs/data/databriefs/db136.pdf
- 444 24. Lokken EM, Walker CL, Delaney S, Kachikis A, Kretzer NM, Erickson A, et al. Clinical
- Characteristics of 46 Pregnant Women with a SARS-CoV-2 Infection in Washington State.
- 446 Am J Obstet Gynecol. 2020;
- 447 25. Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. Clinical features and obstetric and
- neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective,
- single-centre, descriptive study. Lancet Infect Dis. 2020;
- 450 26. Yang Z, Wang M, Zhu Z, Liu Y. Coronavirus Disease 2019 (COVID-19) and Pregnancy: A
- 451 Systematic Review. J Matern Fetal Neonatal Med. 2020; Apr 30:1–4.
- 452 27. Li J, Xue H, Yuan Yuan, Wei Z, Li X, Zhang Y, et al. Meta-analysis Investigating the
- Relationship Between Clinical Features, Outcomes, and Severity of Severe Acute
- 454 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pneumonia. Am J Infect Control.
- 455 2020;Jun 12(S0196-6553(20)30369-2).
- 456 28. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus
- 457 associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab
- 458 Syndr Clin Res Rev. 2020;

29. 459 Ellington S, Strid P, Tong VT, Woodworth K, Galang RR, Zambrano LD, et al. 460 Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 461 Infection by Pregnancy Status — United States, January 22–June 7, 2020. MMWR Morb 462 Mortal Wkly Rep. 2020; 463 30. Li N, Han L, Peng M, Lv Y, Ouyang Y, Liu K, et al. Maternal and neonatal outcomes of 464 pregnant women with COVID-19 pneumonia: a case-control study. Clin Infect Dis. 2020; 31. 465 Qiao J. What are the risks of COVID-19 infection in pregnant women? The Lancet. 2020. 466 32. Gardner MO, Doyle NM. Asthma in pregnancy. Obstetrics and Gynecology Clinics of North 467 America. 2004. 468 33. Angeli F, Spanevello A, De Ponti R, Visca D, Marazzato J, Palmiotto G, et al. 469 Electrocardiographic features of patients with COVID-19 pneumonia. Eur J Intern Med. 470 2020; 471 34. Kayem G, Lecarpentier E, Deruelle P, Bretelle F, Schmitz T, Alessandrini V, et al. A 472 snapshot of the Covid-19 pandemic among pregnant women in France. J Gynecol Obstet 473 Hum Reprod. 2020; 474 475

Table 1. Characteristics of the two cohorts, presented as percentages and means (standard deviations) in the cohorts. Except for group age, percentages and means are age standardized to the pregnant population age distribution in each cohort. Adjustment for survey weights was applied to the replication cohort. Self-report of being seen at a hospital was used as a proxy for hospitalization in the replication cohort.

	Discovery Cohort			Replication Cohort		
	All	Non-	Pregnant	All	Non-	Pregnant
	(N=400,	pregnant	(N=14,04	(N=1,34	pregnant	(N=41,796)
	750)	(N=386,70	9)	4,966)	(N=1,303,1	
		1)			70)	
Age (years)	32.1	32.1 (7.3)	32.4 (4.9)	29.0	29.0 (0.01)	29.0 (0.05)
(not age-	(7.2)			(0.02)		
standardized)						
Tested	7.0%	6.1%	8.0%	2.5%	2.4%	2.7%
Positive	0.6%	0.7%	0.6%	0.4%	0.4%	0.4%
Negative	5.5%	4.9%	6.2%	2.2%	2.1%	2.2%
Suspected	5.6%	6.7%	4.5%	3.5%	4.0%	3.0%
Comorbidities						
Diabetes	1.8%	1.2%	2.3%	3.9%	3.5%	4.3%
Lung	12.9%	12.8%	11.3%	19.3%	19.8%	18.8%
Heart	0.6%	0.5%	0.6%	0.8%	0.9%	0.7%
Kidney	0.3%	0.4%	0.3%	0.6%	0.7%	0.5%
Cancer	0.1%	0.2%	0.1%	0.9%	1.1%	0.8%
Symptom	0.07	0.07 (0.11)	0.04	0.08	0.08	0.07 (0.001)
Severity	(0.11)		(0.09)	(0.0005)	(0.0003)	
Test positive and	0.09%	0.07%	0.1%	0.06 %	0.03%	0.09%
hospitalized*						
Suspected	0.16%	0.16%	0.15%	0.17 %	0.12%	0.23%
positive and						
Hospitalized*						
	<u> </u>	<u>I</u>	1	<u> </u>	1	

- * Hospitalization not queried in replication cohort. Proportion of who tested positive or were
- suspected positive and who reported seeking care at a hospital for symptoms in the prior 24 hours
- 483 provided as a proxy.

Table 2. Frequencies and percentage values of presentation of each symptom among hospitalized in the discovery cohort, and among all women who self-reported being seen at a hospital for their illness in the replication cohort (as hospitalization data were not available). Data are reported by pregnancy status and further subdivided by SARS-CoV-2 test positive or suspected COVID-19 status. Data are reported as N (%) in the discovery cohort, and N surveys (survey-weight adjusted %) in the replication cohort. *Fatigue* was mapped to *tiredness/exhaustion* and *unusual muscle pain* to pain in muscle and joints in the replication cohort. Symptoms not ascertained or mapped in either cohort are marked as not available (NA).

		Discovery Co	hort			Replication	Cohort		
Cluster (body system)	Symptom	Hospitalised non pregnant positive (N=229)	Hospitalised non pregnant suspected positive (N=591)	Hospitalised pregnant positive (N=15)	Hospitalised pregnant suspected positive (N=21)	Seen at hospital, non-pregnant positive (N=300)	Seen at hospital, non-pregnant suspected positive (N=1395)	Seen at hospital, pregnant positive (N=29)	Seen at hospital, pregnant suspected positive (N=75)
Inflammation	Fever	151 (65.9)	359 (60.7)	8 (53.3)	12 (57.1)	135 (48.1)	514 (39.0)	12 (50.6)	19 (29.9)
	Unusual muscle pain	121 (52.8)	338 (57.2)	9 (60.0)	9 (42.9)	199 (69.0)	1,048 (77.0)	19 (76.2)	52 (71.8)
	Fatigue	125 (54.6)	345 (58.4)	10 (66.7)	8 (38.1)	207 (65.9)	1,142 (79.8)	24 (87.5)	61 (84.0)
Neurologic	Headache	185 (80.8)	516 (87.3)	12 (80.0)	17 (81.0)	NA	NA	NA	NA

	Delirium	88 (38.4)	253 (42.8)	4 (26.7)	1 (4.8)	NA	NA	NA	NA
Cardiopulmonary	Dyspnea	113 (49.3)	316 (53.5)	9 (60.0)	11 (52.4)	166 (54.8)	913(65.1)	20 (73.6)	47 (66.9)
	Persistent cough	178 (77.7)	438 (74.1)	12 (80.0)	19 (90.5)	202 (68.2)	1,161 (82.3)	24 (84.6)	61 (81.0)
	Chest pain	170 (74.2)	463 (78.3)	11 (73.3)	14 (66.7)	156 (53.2)	787 (56.8)	17 (62.3)	34 (51.9)
	Difficulty breathing	NA	NA	NA	NA	144 (47.7)	710 (51.6)	16 (56.0)	36 (55.1)
Oropharyngeal	Hoarse voice	117 (51.1)	309 (52.3)	6 (40.0)	11 (52.4)	NA	NA	NA	NA
	Sore throat	148 (64.6)	371 (62.8)	10 (66.7)	14 (66.7)	118 (38.3)	552(39.1)	15 (59.0)	29 (46.7)
	Nasal congestion	NA	NA	NA	NA	146 (48.4)	719 (51.5)	19 (61.5)	45 (56.2)
	Runny nose	NA	NA	NA	NA	116 (35.9)	636 (48.5)	14 (57.0)	33 (51.4)
Anosmia/ageusia	Anosmia	177 (77.3)	481 (81.4)	12 (80.0)	19 (90.5)	182 (63.1)	786 (56.7)	20 (75.2)	47 (70.4)
Gastrointestinal	Skipped meals	153 (66.8)	400 (67.7)	7 (46.7)	11 (52.4)	NA	NA	NA	NA
	Abdominal pain	115 (50.2)	274 (46.4)	9 (60.0)	10 (47.6)	NA	NA	NA	NA
	Diarrhoea	126 (55.0)	275 (46.5)	7 (46.7)	11 (52.4)	137 (49.2)	611 (44.4)	17 (59.8)	39 (56.1)
	Nausea or	NA	NA	NA	NA	138 (49.4)	633 (49.8)	21 (78.2)	51 (79.4)

vomiting			

Table 3. Frequencies and percentages of comorbidities and pre-existing conditions in the discovery and replication cohorts. Columns refer to pregnant women tested and suspected positive for SARS-CoV-2 infection. Data are reported as N (%). Data from the replication cohort are reported as N surveys (survey-weight adjusted %). Conditions not ascertained or mapped in either cohort are marked as not available (NA).

	Discovery Coho	ort	Replication Cohort	i	
Comorbidity or pre- existing condition	Pregnant test positive (N=79)	Pregnant suspected positive (N=629)	Pregnant test positive (N=134)	Pregnant suspected positive (N=1076)	
Diabetes	3 (3.8)	15 (2.4)	11 (8.9)	76 (7.4)	
Lung disease	8 (10.1)	80 (12.7)	37 (31)	376 (34.2)	
Heart disease	1 (1.3)	5 (0.8)	5 (6.3)	41 (4.8)	
Kidney disease	0 (0.0)	2 (0.3)	8 (7.8)	30 (43.3)	
Hypertension	NA	NA	17 (13.9)	170 (15.4)	
Autoimmune	0 (0.0)	8 (1.3)	14 (11.5)	106 (9.3)	
Cancer	0 (0.0)	1 (0.2)	5 (4.7)	29 (3.2)	
Smoking /	6 (7.6)	36 (5.7)	NA	NA	
Past smoker	13 (16.5)	121 (19.2)			

Figure 1. Receiver Operating Characteristics curve showing validation of the imputation of SARS-CoV-2 test status using the mapped symptom score probability in the replication cohort. Area under the curve is 74%.




Figure 2. Comparison of symptoms presentation in the discovery (DC) and replication (RC) cohorts. Results refer to non-pregnant (orange) and pregnant (blue) women tested positive and suspected positive for SARS-CoV-2 and who required hospitalization (in DC, darker shade) or were seen at the hospital (RC, lighter shade). Results are reported as age-standardized percentage of women reporting each symptom in each sub-cohort.




Figure 3. Symptom profile of hospitalized and non-hospitalized pregnant and non-pregnant women positive and suspected positive to SARS-CoV-2 in the discovery cohort. Results are reported in percentage of women reporting each symptom in each group.

